NCT05558059Recruiting
Imaging Retinal Vasculature in Infant Eyes
Elucidating Perifoveal Vasculature Development in Infants
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
Retinopathy of prematurity is a leading cause of childhood blindness worldwide. The fovea, a critical location in the retina determining visual acuity and visual function, and the blood vessels around it, are abnormally developed in infants with retinopathy of prematurity. However, how these blood vessels form during development of the human fovea remains unclear. This research will advance our understanding of the fundamental knowledge of how the blood vessels around the fovea form in infants, and how they change in diseased states such as preterm birth or retinopathy of prematurity.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 16 (estimated)
- First submitted
- 6 Sept 2022
- Start date
- 3 Oct 2024
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- Duke University
- NCT number
- NCT05558059
What you commit to
- Study type: Observational
- Planned participants: 16
- From 3 Oct 2024 to the primary completion date, 31 Aug 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Infant has a health or eye condition that preclude eye examination or retinal imaging (e.g. corneal opacity such as with Peter's anomaly or cataract)
- Infant has a health condition, other than prematurity, that has a profound impact on brain development (e.g. anencephaly)
Other
- Participant or Parent/Legal Guardian unwilling or unable to provide consent
Who the study is looking for
- Health care provider, knowledgeable of protocol, agrees that study personnel could contact the Parent/Legal guardian
- Parent/Legal Guardian is able and willing to consent to study participation for the infant
- Infant meets the American Association of Pediatrics eligibility of ROP screening, and is age less than 34 6/7 weeks postmenstrual age at first visit
Age in the registry: - to 2 months · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke University Coordinator of this site? Confirm its status | Durham | United States | Recruiting |
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphi | United States | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.